Sangamo Therapeutics (NASDAQ: SGMO)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sangamo Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sangamo Therapeutics Company Info
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
News & Analysis
These exchange-traded funds track companies in this biotech space.
Here's an overview of the opportunities in gene editing and CRISPR technology.
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.
Each company aims to use its genome editing platform to treat disease, but which has an edge?
Which stock wins in a battle between these two clinical-stage biotechs?
Which of these two gene-editing companies is the better investment?
With the coronavirus pandemic on everyone's mind, these three promising stocks have stayed under the radar.
Valuation
Earnings Transcripts
SGMO earnings call for the period ending October 3, 2021.
SGMO earnings call for the period ending June 3, 2021.
SGMO earnings call for the period ending March 31, 2021.
SGMO earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.